Italia markets closed

MRSN Jan 2026 3.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,14000,0000 (0,00%)
Alla chiusura: 02:27PM EDT
Schermo intero
Chiusura precedente1,1400
Aperto1,1400
Denaro0,6000
Domanda2,0000
Prezzo d'esercizio3,00
Scadenza2026-01-16
Min-Max giorno1,1400 - 1,1400
Contratto - Min-MaxN/D
Volume5
Open Interest3,85k
  • GlobeNewswire

    Mersana Therapeutics Announces Changes in Leadership

    Dr. Martin Huber Martin Huber, M.D., has been named President and Chief Executive Officer of Mersana Therapeutics, Inc., effective September 11, 2023. Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOB

  • GlobeNewswire

    Mersana Therapeutics Announces Second Quarter 2023 Financial Results

    Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan commitments into 2026 CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update a

  • GlobeNewswire

    Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on August 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 38,775 shares of its common stock an